Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 W 4th Avenue, Vancouver, Canada

Stocktradesmoon Jul. 15 at 7:01 PM

$ABCL AbCellera DEEP DIVE https://x.com/9_Invest_obey/status/2077295224049823754

0 · Reply

tradersunion353 Jul. 15 at 5:39 PM

$ABCL Give me 13 dollars already Such a boring overhyped junk

1 · Reply

Samb2344 Jul. 15 at 4:46 PM

$ABCL cmon bro

0 · Reply

PamelaJorge270 Jul. 15 at 3:32 PM

$ABCL has an interesting setup from a sentiment perspective. Not making a technical prediction, but the stock has repeatedly shown a pattern of sharp moves followed by pullbacks and rebounds. The bigger catalyst now is approaching: upcoming clinical readouts, potentially as early as the next earnings update. Technical patterns can be interesting, but for biotech names the real driver is always the data. If the readouts are positive, that will matter far more than any chart formation.

1 · Reply

Ckkung71 Jul. 15 at 3:16 PM

$ABCL Everybody is excited of the results of phase 2 on 635. I asking you: Do you think they will wait fore the result or will they stay with 20-25% shorted stocks. If they do its must be a big institution No one else can do that. Or what?

1 · Reply

TradeIntelligence_ Jul. 15 at 1:32 PM

Top Multi-Year Growth Plays I’m Watching These are the companies with long-term potential in some of the biggest future markets: $QS -Next-generation battery technology with a focus on the future of energy storage. $SMR -Small modular nuclear reactor play targeting the growing demand for clean power. $JOBY -Electric aviation company aiming to transform urban transportation. $ABCL -AI-driven biotech platform combining advanced technology with drug discovery. $RXRX -AI-powered pharmaceutical company building the future of medicine. Long-term winners are often built before the market fully recognizes the opportunity.

1 · Reply

tradersunion353 Jul. 15 at 1:10 PM

$ABCL over hyped underperforming pos how many years ceo and pumpers gonna do this drama “we dont care for share price we care science” hello clowns investors needs returns along with science

0 · Reply

Ckkung71 Jul. 15 at 6:30 AM

$ABCL Higher then ever..

1 · Reply

snowPOW Jul. 15 at 4:58 AM

$ABCL I don't even feel bad averaging up. I plan to make a buy, relatively soon. Big for me, probably insignificant to a chart. This has been cheap for so long, I should've bought before. To 20B, the launch pad to multiples. Undervalued. Hasn't even been set up for lift off

3 · Reply

Samb2344 Jul. 15 at 2:26 AM

$ABCL higher

0 · Reply

3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts

NUVB SERV UBER

Jul 7, 2026, 4:05 PM EDT - 8 days ago

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

2026-07-07T10:35:14.000Z - 8 days ago

AbCellera upgraded to Buy from Hold at Benchmark

JAZZ

2026-07-06T13:15:29.000Z - 9 days ago

AbCellera apponts Lynn Seely to board of directors

LYEL

Jul 6, 2026, 9:00 AM EDT - 9 days ago

AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jun 17, 2026, 7:43 AM EDT - 4 weeks ago

Jazz Pharma, AbCellera ink antibody deal worth up to $876 million

JAZZ

Jun 17, 2026, 7:00 AM EDT - 4 weeks ago

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

2026-06-05T13:05:56.000Z - 5 weeks ago

AbCellera appoints Victor Sandor to board of directors

Jun 5, 2026, 9:00 AM EDT - 5 weeks ago

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

Jun 4, 2026, 11:40 AM EDT - 5 weeks ago

AbCellera Biologics Transcript: Jefferies Global Healthcare Conference 2026

May 13, 2026, 8:00 PM EDT - 2 months ago

AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

2026-05-12T10:58:11.000Z - 2 months ago

AbCellera price target raised to $8 from $7 at Stifel

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Slides: Q1 2026

May 11, 2026, 4:05 PM EDT - 2 months ago

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

May 7, 2026, 4:05 PM EDT - 2 months ago

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

2026-05-05T10:36:31.000Z - 2 months ago

AbCellera initiated with an Overweight at Cantor Fitzgerald

Apr 29, 2026, 8:00 AM EDT - 2 months ago

AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

AbCellera Biologics Proxy statement: Proxy filing

Apr 21, 2026, 1:30 PM EDT - 3 months ago

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 20, 2026, 9:00 AM EDT - 3 months ago

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

2026-04-09T20:10:26.000Z - 3 months ago

AbCellera initiated with a Buy at JonesResearch

Apr 1, 2026, 4:05 PM EDT - 3 months ago

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Mar 17, 2026, 4:30 PM EDT - 4 months ago

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 4, 2026, 9:50 AM EST - 4 months ago

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Slides: Q4 2025

2026-02-24T21:15:21.000Z - 5 months ago

AbCellera reports FY25 EPS (49c) vs. (55c) last year

Feb 24, 2026, 4:05 PM EST - 5 months ago

AbCellera Reports Full Year 2025 Business Results

Feb 11, 2026, 4:05 PM EST - 5 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Jan 22, 2026, 4:05 PM EST - 6 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 14, 2026, 6:45 PM EST - 6 months ago

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 7:00 AM EST - 6 months ago

AbCellera Biologics Slides: Corporate presentation

2026-01-12T14:36:23.000Z - 6 months ago

AbCellera doses first patients in Phase 2 portion of ABCL635 trial

Jan 12, 2026, 9:00 AM EST - 6 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

2025-12-18T14:20:19.000Z - 7 months ago

AbCellera to receive $36M upfront in patent litigation settlement with Bruker

BRKR

Dec 18, 2025, 9:00 AM EST - 7 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 8, 2025, 4:05 PM EST - 7 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 3, 2025, 8:00 AM EST - 8 months ago

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 8:00 AM EST - 8 months ago

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 9:00 AM EST - 8 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 4:05 PM EST - 8 months ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 10 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Sep 29, 2025, 4:05 PM EDT - 10 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 10, 2025, 9:07 AM EDT - 11 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 5, 2025, 9:30 AM EDT - 11 months ago

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 27, 2025, 9:00 AM EDT - 11 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 1, 2025, 7:00 AM EDT - 1 year ago

AbCellera Biologics Slides: Corporate Presentation

Jul 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jun 9, 2025, 10:40 AM EDT - 1 year ago

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

May 30, 2025, 1:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

May 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 19, 2025, 1:30 PM EDT - 1 year ago

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

Mar 3, 2025, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Dec 3, 2024, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 19, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 17, 2024, 11:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 5, 2024, 3:00 PM EDT - 2 years ago

AbCellera Biologics Transcript: 2024 Wells Fargo Healthcare Conference

Aug 29, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at Upcoming Investor Conferences in September

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q2 2024

Aug 6, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q2 2024 Business Results

Jul 31, 2024, 9:00 AM EDT - 2 years ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jun 25, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 10, 2024, 3:20 PM EDT - 2 years ago

AbCellera Biologics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

May 28, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q1 2024

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results

May 1, 2024, 9:00 AM EDT - 2 years ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

Stocktradesmoon Jul. 15 at 7:01 PM

$ABCL AbCellera DEEP DIVE https://x.com/9_Invest_obey/status/2077295224049823754

0 · Reply

tradersunion353 Jul. 15 at 5:39 PM

$ABCL Give me 13 dollars already Such a boring overhyped junk

1 · Reply

Samb2344 Jul. 15 at 4:46 PM

$ABCL cmon bro

0 · Reply

PamelaJorge270 Jul. 15 at 3:32 PM

1 · Reply

Ckkung71 Jul. 15 at 3:16 PM

1 · Reply

TradeIntelligence_ Jul. 15 at 1:32 PM

1 · Reply

tradersunion353 Jul. 15 at 1:10 PM

$ABCL over hyped underperforming pos how many years ceo and pumpers gonna do this drama “we dont care for share price we care science” hello clowns investors needs returns along with science

0 · Reply

Ckkung71 Jul. 15 at 6:30 AM

$ABCL Higher then ever..

1 · Reply

snowPOW Jul. 15 at 4:58 AM

3 · Reply

Samb2344 Jul. 15 at 2:26 AM

$ABCL higher

0 · Reply

DeMampCamp Jul. 14 at 11:53 PM

$ABCL If there’s one piece of advice I have for management as far as ABCL635 is don’t publicly announce when the results are out, that keeps the short term flippers and shorts on their toes! Just release the PR and discuss the results following said release. Now what they said, I don’t know all of the SEC rules, so I may be missing something! Nice to finally see some green today!

0 · Reply

Stocktradesmoon Jul. 14 at 10:47 PM

$ABCL $ABCL One leadership trait I appreciate is vision, and Carl Hansen has it. Everyone's talking about antibody discovery now, but AbCellera decided to go all-in on this tech over a decade ago. How did he know back then that therapeutic antibodies were the future? What did he see? When Hansen founded AbCellera in 2012 out of his academic lab at the University of British Columbia, his foresight specifically zeroed in on antibodies as the ultimate therapeutic modality. He explained the foundational thesis of the company by stating: "the core idea was that we were going to use microfluidics to be able to enable very rapid scalable analysis of the properties of individual cells and that the cells we're going to look at were the immune cells... because those cells... make different molecules called antibodies and it turns out people actually care about antibodies because they are the largest and still, in an absolute terms, the fastest growing class of therapeutics that exist".

0 · Reply

Stocktradesmoon Jul. 14 at 10:46 PM

$ABCL His foresight was fundamentally rooted in identifying a massive technological shift and recognizing that the biotechnology industry lacked the necessary tools to efficiently harness it. Hansen's initial intuition about the future of medicine actually prompted him to abandon a promising career path in physics. After completing his undergraduate training, he realized that the field had largely moved past its golden age of fundamental discovery. Recognizing the inflection point occurring in the life sciences around 2001, particularly with the sequencing of the human genome, he noted, "I had some intuition that biology was really taking off so I moved from my physics training and I tried to get into biology". He observed that the cost and speed of reading DNA was advancing at a rate that "outpaces Moore's law by orders of magnitude," leading him to conclude that biotechnology would become the most important sector for scientific discovery in the coming decades.

0 · Reply

Stocktradesmoon Jul. 14 at 10:45 PM

$ABCL Instead of taking the traditional, highly risky route of trying to develop a single drug from scratch, Hansen’s early vision was to solve the industry's bottleneck in drug creation AbCellera believes there has been chronic underinvestment in developing drug-creation capabilities for antibody medicines. Hansen recognized that the process of discovering drugs was simply too slow and prone to failure, so he positioned AbCellera as a technology provider. This early vision of acting as an advanced technological engine for the industry ultimately allowed AbCellera to build a massive portfolio of downstream economic stakes in partnered programs without bearing the traditional costs and risks of clinical trials. It now also serves as the foundation for their internal antibody pipeline.

0 · Reply

Stocktradesmoon Jul. 14 at 10:45 PM

$ABCL Looking forward, Hansen's foresight continues to anticipate the evolution of antibody therapies. He notes that while the initial multi-billion-dollar market explosion was driven by simple, standard monoclonal antibodies, the future lies in highly engineered formats. He's stated that "what you're seeing now that's the next wave is bispecific antibodies antibody drug conjugates multispecific antibodies radioisotope antibodies there's a Cambrian explosion of modalities that use the advantages of antibodies in unique ways," predicting that this will be the next massive wave of innovation in therapeutic medicines. According to management, global therapeutic antibody sales amounted to about $300 billion in 2025 and the market is expected to grow to over $500 billion by 2030.

0 · Reply

OctahedronOmega Jul. 14 at 9:48 PM

$ABCL More of a broader FDA signal than a direct near-term catalyst for one biotech. FDA is still refining how it handles AI-driven medical software and digital health. The key watchpoint: it’s collecting input through Aug 13, 2026 on some software functions that fall outside medical device classification and on patient safety.

0 · Reply

TradeX_ Jul. 14 at 8:00 PM

Looks like BMGL might be the next 800% runner. Crazy market! Every micro float ticker has been going parabolic this month. Would not be surprised if they send BMGL up now. BMGL starting to make its move now! Only 750k shares outstanding! 💎 $ABCL $FBIO $TGTX 0s

3 · Reply

Stocktradesmoon Jul. 14 at 7:10 PM

$ABCL $ABCL bulls holding strong at the $6.52 support 💪 That’s the top of wave 1. Wave 4 usually doesn’t break below it in Elliott Wave. Clean setup for a bounce into wave 5 🚀 Who else seeing this? 👀

0 · Reply

Stocktradesmoon Jul. 14 at 7:04 PM

$ABCL There is possibility ABCL635 phase 2 Topline data will be on 2nd Quarter call for $ABCL Blinded Ph2 is 1 dose +12 weeks of data collection. First ladies dosed in JAN 26. Could be finished if they had all dosed in FEB/MAR 26 and Carl mentioned high interest.

1 · Reply

Doozio Jul. 14 at 5:13 PM

MNDY 🐑 $$$ patterns retests ONTO turnaround Tuesday’s are as easy as $ABCL n XYZ ENTA 🐒🍌🧠⏰♾️

0 · Reply

GoldenGateGamma Jul. 14 at 5:06 PM

Epictetus said, “No great thing is created suddenly.” That’s how I view $ABCL. The hardest part of owning a long-term idea is watching the stock do nothing while the market runs higher. Every pullback tests your conviction, but real reratings rarely happen from one headline or one green candle. They happen when a company keeps executing until the market is forced to recognize the progress. The patience part is usually where the edge is built.

0 · Reply

tradersunion353 Jul. 14 at 3:16 PM

$ABCL hey paper traders who get psyched up every time this POS drops how is your adding and loading paper trading working??? DEMMP clown is that you who is creating multiple accounts to pump thjis POS

2 · Reply

Market Cap	1.99B
Revenue (ttm)	75.13M
Net Income (ttm)	-146.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-194.88%
Debt to Equity Ratio	0.00

Volume	3,257,586
Avg Vol	8,275,624
Day's Range	N/A - N/A
Shares Out	305.38M
Stochastic %K	17%
Beta	1.14
Analysts	Strong Sell
Price Target	$10.50